Cellectis S.A.

Equities

ALCLS

FR0010425595

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 09:05:15 25/06/2024 pm IST			Pre-market 11:31:02 am
1.72 ^EUR	-1.71%		1.772	+3.02%

21/06	European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But End Week Higher	MT
20/06	European Equities Traded in the US as American Depositary Receipts Move Higher in Thursday Trading	MT

Cellectis S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 29, 2024 at 01:47 am IST

Cellectis S.A. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 4.53 million compared to USD 0.139 million a year ago. Revenue was USD 6.5 million compared to USD 3.56 million a year ago.

Net income was USD 5.64 million compared to net loss of USD 30.07 million a year ago. Basic earnings per share was USD 0.08 compared to basic loss per share of USD 0.58 a year ago. Diluted loss per share was USD 0.15 compared to USD 0.58 a year ago.

Latest news about Cellectis S.A.

European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But End Week Higher	21/06	MT
European Equities Traded in the US as American Depositary Receipts Move Higher in Thursday Trading	20/06	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading	18/06	MT
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading	17/06	MT
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading	14/06	MT
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Thursday Trading	13/06	MT
Cellectis Announces the Publication of A Scientific Article in Nature Communications	13/06	CI
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading	12/06	MT
Oppenheimer Trims Cellectis Price Target to $10 From $11, Maintains Outperform Rating	12/06	MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading	11/06	MT
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading	10/06	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	07/06	MT
Tech Firms Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	06/06	MT
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	05/06	MT
Cellectis: orphan drug designation in ALL	05/06	CF
Cellectis Gets Orphan Drug Label From European Commission For Acute Lymphoblastic Leukemia	05/06	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	04/06	MT
European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower	31/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading	29/05	MT
Transcript : Cellectis S.A., Q1 2024 Earnings Call, May 29, 2024	29/05
Cellectis: operations financed until 2026	29/05	CF
Earnings Flash (CLLS) CELLECTIS Posts Q1 Revenue $6.5M	29/05	MT
Cellectis S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/05	CI
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading	28/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower	24/05	MT

Chart Cellectis S.A.

Duration

Period

More charts

Company Profile

Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR-T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR-T cells for the treatment of cancer patients, and a platform for performing therapeutic genetic modifications in hematopoietic stem cells in a various diseases. Capitalizing on its 23 years of expertise in genome engineering, its TALEN® genome editing technology and its pioneering PulseAgile electroporation technology, Cellectis S.A. is developing innovative product candidates using the power of the immune system to treat diseases with unmet medical needs. As part of its commitment to the search for curative cancer therapies, Cellectis S.A. is developing UCART product candidates directed at the unmet medical needs of patients with certain types of cancer, including acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma. HEAL is a new platform focused on hematopoietic stem cells for the treatment of blood disorders, immune deficiencies, and lysosomal storage diseases.

Sector

Biotechnology & Medical Research

Calendar

28/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Cellectis S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CELLECTIS S.A.	-37.77%	133M
MODERNA, INC.	+38.36%	52.73B
LONZA GROUP AG	+36.73%	39B
IQVIA HOLDINGS INC.	-8.63%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+25.46%	30.38B
CELLTRION, INC.	-11.17%	26.39B
ICON PUBLIC LIMITED COMPANY	+11.44%	26.08B
UNITED THERAPEUTICS CORPORATION	+45.09%	14.15B
MEDPACE HOLDINGS, INC.	+32.93%	12.6B
BIO-TECHNE CORPORATION	-5.30%	11.51B

Other Biotechnology & Medical Research